Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Evaxion Biotech A/S has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners. The prosecution activity is spread across 3 distinct art units. This distribution indicates that while each action has a unique examiner, there is some overlap in the specialized divisions reviewing the company's applications.
GANGLE, BRIAN J is the busiest examiner for the portfolio, managing 1 pending office action. This represents a portion of the 4 total pending office actions. The use of 3 distinct art units for the distinct examiners suggests that multiple examiners are working within the same art unit. This concentration within the Biotechnology & Pharmaceuticals area requires the company to manage multiple examiner relationships across a small number of specialized units. The strategy for these applications must account for the specific scientific standards of the three art units involved. By coordinating responses across the examiners, the company can work toward a consistent patent position in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | ZEMAN, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18999335 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae | GANGLE, BRIAN J | — |
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | ZEMAN, ROBERT A | — |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999335 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae | GANGLE, BRIAN J | — | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | ZEMAN, ROBERT A | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jun 04, 2024 |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | DENT, ALANA HARRIS | 1643 | DP | Final Rejection | — | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial